This page documents the priority claims and modern relevance of each of the eight papers published by H. B. F. Antaki between 1951 and 1967. Every claim rests on a primary source: the published papers, patent specifications verified at text level, and canonical review literature. The table is a scholarly reference record, not a summary.
All 25 pharmaceutical patents citing his work are verified at text level against USPTO, EPO, and WIPO databases, April 2026. Ten assignee families. Six countries. 1970–2016.
| Contribution | Year | Reference Paper | Priority Claim | Modern Relevance |
|---|---|---|---|---|
| Pyrido[1,2-a]pyrimidine structural correction | 1951 | J. Chem. Soc., 1951, 551–555 | First unequivocal proof of 4-oxo structure, correcting 40-year error (Palazzo 1911, repeated by Seide 1925, Crippa & Scevola 1937, Khitrik 1939). Confirmed by Adams & Pachter 1952. Described as "unequivocal synthesis" by Hermecz & Mészáros, Adv. Heterocycl. Chem. 33 (1983), cited at pages 251, 256, 264, 269, 319. | Core scaffold of kinase inhibitors. Cited in Pfizer US 4,041,163 and US 4,066,766. Referenced in Hermecz, Adv. Heterocycl. Chem. 73 (1999) as references 2 and 3 of 350. Listed in e-EROS (Wiley, 2001) as Reference 1(a).
Wikipedia: 4H-Pyrido[1,2-a]pyrimidin-4-one Wikidata: Hekmat Antaki (Q138809036) |
| Pyrimido[1,2-a]quinoline synthesis | 1951 | J. Chem. Soc., 1951, 551–555 | First reported synthesis of 1H-pyrimido[1,2-a]quinoline. Pfizer US 4,066,766 (1978): "The synthesis of a 1H-pyrimido[1,2-a]quinoline appears to have first been reported by Antaki et al." | Anticancer DNA intercalators, antivirals, fluorescent materials. The antischistosomal activity of the compound was documented by Pfizer in 1978, citing the 1958 JACS paper. |
| Thiazolo[3,2-a]pyrimidine synthesis | 1951 | J. Chem. Soc., 1951, 551–555 | First aromatic thiazolo[3,2-a]pyrimidine reported. Cited in Pfizer US 4,041,163 (1977): "The pyrimido[2,1-b]benzothiazole ring system was first reported by Antaki, et al." — declarative, no hedge. | Anti-inflammatory, antiviral, antibacterial scaffold. Cited in Pfizer, Mead Johnson, and CIBA patent filings. |
| Heterocyclic steroid derivatives | 1951 | J. Chem. Soc., 1951, 901–904 | First systematic fusion of quinoline, indole, pyrrole, thiazole, and benzimidazole to cholestane/allocholane scaffolds, designed for biological evaluation. Biological evaluation conducted at The British Drug Houses. | Steroid-quinoline hybrids as antimalarials; indolo-steroids as neurosteroid/anticancer candidates. Cited in Zhungietu & Dorofeenko, Russ. Chem. Rev. 36 (1967). |
| Halogenated glycosylbenzimidazoles | 1951 | J. Chem. Soc., 1951, 2873–2877 | First 5-chloro- and 5,6-dichloro-1-glycosylbenzimidazoles and first 2-methyl-1-glycosylbenzimidazoles. Novel glycosylation route via N-glycosyl-o-phenylenediamine and ethyl orthoacetate. Designed as vitamin B12 antagonists following Brink & Folkers (1949–1950). | Halogenated benzimidazole nucleosides as antiviral and antitumour candidates. Purine bioisostere concept. |
| UV chromophore assignment | 1958 | J. Am. Chem. Soc., 1958, 80, 3066–3069 | First systematic UV absorption standards for the pyrido[1,2-a]pyrimidine class. Identified constant absorption at 330–390 mμ and provided the mechanistic explanation. Confirmed by Shur & Israelstam, J. Org. Chem. 33 (1968). Adopted as standard reference by Hermecz & Mészáros (1983). Listed as Reference 1(a) in Wiley e-EROS (2001). | Diagnostic band used for metabolite identification and compound verification in pharmaceutical research. "This may be considered as evidence for the major contribution of zwitterionic fully aromatic structures such as VIII to the resonance state of the molecule." — Antaki, JACS 1958. |
| Schistosomicidal pyrido[1,2-a]pyrimidines | 1962 | J. Org. Chem., 1962, 27, 1371–1374 | First 2-methyl-3-cyano-4H-pyrido[1,2-a]pyrimidin-4-ones. Explicit schistosomicidal programme: "In continuation of previous work on the schistosomicidal activity in the pyrido[1,2-a]pyrimidine series." Submitted from home address, Agouza, Cairo — no institutional affiliation. | 2-Me-3-CN core in modern PI3K/CDK/JAK inhibitors. Antischistosomal evaluation of related scaffolds continuing (Oliveira et al., 2026). |
| Hexahydroquinoline synthesis — The Antaki Synthesis | 1963 | J. Chem. Soc., 1963, 4877–4879 | First practical three-component hexahydroquinoline synthesis via cyclohexane-1,3-dione condensation. Named the "Antaki Synthesis" in Oduselu et al., Front. Chem. 14 (2026) — listed as one of three classical methods alongside Hantzsch and Stankevich. Cited by Bossert & Vater (1989): "aroused our interest." Cited independently by USPTO examiner in Zeneca US 5,455,253 (1994). Seven ICI/Zeneca patents across USA, Europe, and Canada cite the paper for both compounds and reaction conditions. | Antimalarial candidate confirmed against P. falciparum (Vanaerschot et al., Nat. Microbiol. 2017). Cited in 25 pharmaceutical patents 1970–2016. Most recent: US9745274, Shin Nippon Biomedical Laboratories, Japan, granted 2017, expires 2034 — eighty-three years after the 1951 paper. |
| Decahydroacridine derivatives | 1965 | J. Chem. Soc., 1965, 2263–2264 | First 9,10-diaryl-1,8-dioxodecahydroacridines. Mechanistic proof of xanthene vs acridine interconversion. Bibliography cites Bongartz (1888) and Stobbe & Volland (1902) in the original German — the Partington bibliographic practice applied without interruption from London to Cairo across fifteen years. | Acridinedione core in calcium channel blockers, antitumour agents, and anti-leishmanial candidates. Cited in Acheson, Chemistry of Heterocyclic Compounds, Vol. 9 (1973), references 324 and 325. |
| Benz- and naphth-indenoquinolines | 1967 | J. Chem. Soc. (C), 1967, 1581–1582 | First benzindeno[2,1-c]quinolines and naphthindeno[1,2-b]quinolines via Wolff–Kishner reduction of the 8-oxo precursor. Paper received 18 July 1966. Product exhibited, in the paper's own words, "intense blue fluorescence." Eleven independent research groups (2011–2024) have reproduced the 8-oxo intermediate without completing the Wolff–Kishner step. | Fused indenoquinolines as anticancer topoisomerase inhibitors and DNA intercalators. Fluorescence properties relevant to OLED emitter chemistry and bioimaging probes. |
Full patent table with all 25 verified citations: see main page. Full reception record with direct quotations from patent specifications and review literature: In Their Own Words.